380 related articles for article (PubMed ID: 29633308)
1. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC.
Lee JS; Kang JH; Lee SH; Hong D; Son J; Hong KM; Song J; Kim SY
Cell Death Dis; 2016 Dec; 7(12):e2511. PubMed ID: 27929535
[TBL] [Abstract][Full Text] [Related]
5. Targeting cellular metabolism to reduce head and neck cancer growth.
Yang J; Guo Y; Seo W; Zhang R; Lu C; Wang Y; Luo L; Paul B; Yan W; Saxena D; Li X
Sci Rep; 2019 Mar; 9(1):4995. PubMed ID: 30899051
[TBL] [Abstract][Full Text] [Related]
6. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
[TBL] [Abstract][Full Text] [Related]
8. Altered glutamine metabolism in platinum resistant ovarian cancer.
Hudson CD; Savadelis A; Nagaraj AB; Joseph P; Avril S; DiFeo A; Avril N
Oncotarget; 2016 Jul; 7(27):41637-41649. PubMed ID: 27191653
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus-like Disease in MRL/lpr Mice and Experimental Autoimmune Encephalomyelitis.
Kono M; Yoshida N; Maeda K; Suárez-Fueyo A; Kyttaris VC; Tsokos GC
Arthritis Rheumatol; 2019 Nov; 71(11):1869-1878. PubMed ID: 31233276
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).
Robinson MM; McBryant SJ; Tsukamoto T; Rojas C; Ferraris DV; Hamilton SK; Hansen JC; Curthoys NP
Biochem J; 2007 Sep; 406(3):407-14. PubMed ID: 17581113
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism.
Thangavelu K; Pan CQ; Karlberg T; Balaji G; Uttamchandani M; Suresh V; Schüler H; Low BC; Sivaraman J
Proc Natl Acad Sci U S A; 2012 May; 109(20):7705-10. PubMed ID: 22538822
[TBL] [Abstract][Full Text] [Related]
12. Targeting GLS1 to cancer therapy through glutamine metabolism.
Yu W; Yang X; Zhang Q; Sun L; Yuan S; Xin Y
Clin Transl Oncol; 2021 Nov; 23(11):2253-2268. PubMed ID: 34023970
[TBL] [Abstract][Full Text] [Related]
13. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.
Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W
Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404
[TBL] [Abstract][Full Text] [Related]
14. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate.
Wu B; Liu J; Zhao R; Li Y; Peer J; Braun AL; Zhao L; Wang Y; Tong Z; Huang Y; Zheng JC
J Neuroinflammation; 2018 Mar; 15(1):79. PubMed ID: 29540215
[TBL] [Abstract][Full Text] [Related]
15. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase.
Hartwick EW; Curthoys NP
J Enzyme Inhib Med Chem; 2012 Dec; 27(6):861-7. PubMed ID: 21999665
[TBL] [Abstract][Full Text] [Related]
16. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.
Guo L; Zhou B; Liu Z; Xu Y; Lu H; Xia M; Guo E; Shan W; Chen G; Wang C
Tumour Biol; 2016 Aug; 37(8):11007-15. PubMed ID: 26894601
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
18. Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase.
McDonald CJ; Acheff E; Kennedy R; Taylor L; Curthoys NP
Neurochem Int; 2015 Sep; 88():10-4. PubMed ID: 25510640
[TBL] [Abstract][Full Text] [Related]
19. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
[TBL] [Abstract][Full Text] [Related]
20. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
